Metabolica Drug Discovery

Metabolica Health (officially Metabolica Drug Discovery Inc.) is a preclinical biotechnology company focused on developing microbiome-derived therapies for metabolic diseases. The company's lead candidate is 4-cresol, a small molecule metabolite that targets the biological root of type 2 diabetes by regenerating pancreatic beta-cells and improving systemic metabolism. Metabolica is advancing a tiered pipeline that includes pharmaceutical-grade small molecules, engineered live biotherapeutic products (eLBPs), and natural health solutions. The company leverages global academic partnerships with institutions like INSERM and McGill University to translate its microbiome research into first-in-class treatments for obesity, diabetes, and metabolic liver disease.